Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open-label Fingolimod Clear all
Completed Phase 3 Interventional Results available

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

NCT03623243
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing Multiple Sclerosis, Advancing Multiple Sclerosis
Interventions
Siponimod
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
54
States / cities
Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 21, 2026, 9:15 AM EDT
Completed Early Phase 1 Interventional

A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma

NCT02490930
View directory record Official record
Conditions
Glioblastoma, Anaplastic Astrocytoma
Interventions
Fingolimod
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 21, 2026, 9:15 AM EDT
Completed Early Phase 1 Interventional Results available

Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage

NCT04088630
View directory record Official record
Conditions
Intracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic, Intracerebral Hemorrhage, Hypertensive, Intracerebral Hemorrhage Intraparenchymal
Interventions
Fingolimod, Placebo, Open-label Fingolimod
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 21, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

NCT04353492
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
25
States / cities
Fullerton, California • Aurora, Colorado • Newark, Delaware + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 9:15 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

NCT02342704
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
natalizumab, fingolimod
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
12
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Port Charlotte, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 21, 2026, 9:15 AM EDT
Not listed No phase listed Observational

A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis

NCT01811290
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Simnad, Virginia, M.D.
Individual
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 21, 2026, 9:15 AM EDT
Terminated Phase 4 Interventional Results available

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies

NCT02241785
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Fullerton, California • Aurora, Colorado • Des Moines, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 21, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Results available

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

NCT03257358
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Fingolimod
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
66
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 21, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

NCT01201356
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Fingolimod
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
34
States / cities
Cullman, Alabama • Oceanside, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 21, 2026, 9:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis

NCT02021162
View directory record Official record
Conditions
Multiple Sclerosis, Healthy
Interventions
Not listed
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 21, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Results available

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

NCT01216072
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Fingolimod, Standard MS DMTs
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
142
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 21, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

NCT01623596
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Fingolimod, Disease Modifying therapy
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
122
States / cities
Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 21, 2026, 9:15 AM EDT
Terminated Phase 3 Interventional Results available

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

NCT00731692
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
FTY720, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
25 Years to 65 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
33
States / cities
Newport Beach, California • Sacramento, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 21, 2026, 9:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT01892722
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 21, 2026, 9:15 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT04926818
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Fingolimod, Ofatumumab, Siponimod, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 21, 2026, 9:15 AM EDT